IBTROZI responses now last a median 49.7 months in untreated ROS1 lung cancer. FDA has updated the label
The FDA has approved an IBTROZI label update incorporating a 49.7-month median duration of response from the TRUST-I study in TKI-naïve ROS1-positive NSCLC.
